<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078233</url>
  </required_header>
  <id_info>
    <org_study_id>0518-058</org_study_id>
    <secondary_id>2010_020</secondary_id>
    <secondary_id>EP08025.005</secondary_id>
    <nct_id>NCT01078233</nct_id>
  </id_info>
  <brief_title>Observational Data Analysis in EuroSIDA (MK-0518-058)</brief_title>
  <official_title>Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EuroSIDA Coordinating Centre, Copenhagen HIV Programme (CHIP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to monitor health outcomes associated with antiretroviral
      drugs in a population of HIV-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Time Perspective: Retrospective and Prospective
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2008</start_date>
  <completion_date type="Actual">March 6, 2014</completion_date>
  <primary_completion_date type="Actual">March 6, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Malignancy</measure>
    <time_frame>Historical Cohort: up to 24 months (January 2006 to December 2007); Raltegravir and Concurrent Cohorts: up to 68 months (December 2007 to July 2013)</time_frame>
    <description>All-type malignancy, including both Acquired Immune Deficiency Syndrome (AIDS)-defining and non-AIDS-defining malignancy, was evaluated. Only the first occurrence of any malignancy type was counted for each participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Clinically Important Hepatic Events</measure>
    <time_frame>Historical Cohort: up to 24 months (January 2006 to December 2007); Raltegravir and Concurrent Cohorts: up to 68 months (December 2007 to July 2013)</time_frame>
    <description>Clinically important hepatic events were defined as either 1) hepatic encephalopathy (stage III or IV), or 2) discontinuation of raltegravir use where liver toxicity was listed as the reason for discontinuation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Lipodystrophy</measure>
    <time_frame>Historical Cohort: up to 24 months (January 2006 to December 2007); Raltegravir and Concurrent Cohorts: up to 68 months (December 2007 to July 2013)</time_frame>
    <description>Lipodystrophy events were defined as the first report for either 1) loss of fat from extremities, buttocks, or face, or 2) accumulation of fat in abdomen, neck, breasts, or other defined location.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of All-Cause Mortality</measure>
    <time_frame>Historical Cohort: up to 24 months (January 2006 to December 2007); Raltegravir and Concurrent Cohorts: up to 68 months (December 2007 to July 2013)</time_frame>
    <description>All participant deaths were recorded</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">6617</enrollment>
  <condition>HIV-1 Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir Cohort</arm_group_label>
    <description>Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical Cohort</arm_group_label>
    <description>Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent Cohort</arm_group_label>
    <description>Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults 16 years old and older in the EuroSIDA database
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 16 years old and older with HIV-1

        Exclusion Criteria:

          -  Subjects will be excluded if they have no prospective follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.encepp.eu/encepp/viewResource.htm?id=18914</url>
    <description>EUPAS Register (EUPAS17912)</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <results_first_submitted>June 15, 2015</results_first_submitted>
  <results_first_submitted_qc>August 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 17, 2015</results_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>antiretroviral treatment</keyword>
  <keyword>HIV Cohort</keyword>
  <keyword>Treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0518-058&amp;kw=0518-058&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The analyses in this study are based on data collected from a cohort of HIV-1-infected participants in a setting of routine clinical care in Europe (EuroSIDA Cohort Study). Participants could contribute data to more than one cohort, but no overlap in follow-up time was allowed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir Cohort Only</title>
          <description>Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union). Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in this cohort. These participants contributed data only to the Raltegravir Cohort.</description>
        </group>
        <group group_id="P2">
          <title>Historical and Raltegravir Cohorts Only</title>
          <description>Participants with HIV-1 infection who 1) started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007 and had at least 1 month prospective follow-up in the Historical Cohort, and 2) started raltegravir on or after 21 December 2007 and had at least 1 month prospective follow-up in the Raltegravir Cohort. These participants contributed data to the Historical Cohort and the Raltegravir Cohort.</description>
        </group>
        <group group_id="P3">
          <title>Historical Cohort Only</title>
          <description>Participants with HIV-1 infection who started a new antiretroviral drug as part of a cART regimen on or after 1 January 2006 and before 21 December 2007 and had at least 1 month prospective follow-up in this cohort. These participants contributed data only to the Historical Cohort.</description>
        </group>
        <group group_id="P4">
          <title>Historical and Concurrent Cohorts</title>
          <description>Participants with HIV-1 infection who 1) started a new antiretroviral drug as part of a cART regimen on or after 1 January 2006 and before 21 December 2007 and had at least 1 month prospective follow-up in the Historical Cohort, and 2) started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007, had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. These participants contributed data to the Historical Cohort and the Concurrent Cohort.</description>
        </group>
        <group group_id="P5">
          <title>Concurrent Cohort Only</title>
          <description>Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007, had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. These participants contributed data only to the Concurrent Cohort.</description>
        </group>
        <group group_id="P6">
          <title>Concurrent and Raltegravir Cohorts Only</title>
          <description>Participants with HIV-1 infection who 1) started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007, had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort, and 2) started raltegravir on or after 21 December 2007 and had at least 1 month prospective follow-up in the Raltegravir Cohort. These participants contributed data to the Concurrent Cohort and the Raltegravir Cohort.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="656"/>
                <participants group_id="P2" count="296"/>
                <participants group_id="P3" count="1681"/>
                <participants group_id="P4" count="631"/>
                <participants group_id="P5" count="3199"/>
                <participants group_id="P6" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="656"/>
                <participants group_id="P2" count="296"/>
                <participants group_id="P3" count="1681"/>
                <participants group_id="P4" count="631"/>
                <participants group_id="P5" count="3199"/>
                <participants group_id="P6" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir Cohort Only</title>
          <description>Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union). Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in this cohort. These participants contributed data only to the Raltegravir Cohort.</description>
        </group>
        <group group_id="B2">
          <title>Historical and Raltegravir Cohorts Only</title>
          <description>Participants with HIV-1 infection who 1) started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007 and had at least 1 month prospective follow-up in the Historical Cohort, and 2) started raltegravir on or after 21 December 2007 and had at least 1 month prospective follow-up in the Raltegravir Cohort. These participants contributed data to the Historical Cohort and the Raltegravir Cohort.</description>
        </group>
        <group group_id="B3">
          <title>Historical Cohort Only</title>
          <description>Participants with HIV-1 infection who started a new antiretroviral drug as part of a cART regimen on or after 1 January 2006 and before 21 December 2007 and had at least 1 month prospective follow-up in this cohort. These participants contributed data only to the Historical Cohort.</description>
        </group>
        <group group_id="B4">
          <title>Historical and Concurrent Cohorts</title>
          <description>Participants with HIV-1 infection who 1) started a new antiretroviral drug as part of a cART regimen on or after 1 January 2006 and before 21 December 2007 and had at least 1 month prospective follow-up in the Historical Cohort, and 2) started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007, had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. These participants contributed data to the Historical Cohort and the Concurrent Cohort.</description>
        </group>
        <group group_id="B5">
          <title>Concurrent Cohort Only</title>
          <description>Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007, had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. These participants contributed data only to the Concurrent Cohort.</description>
        </group>
        <group group_id="B6">
          <title>Concurrent and Raltegravir Cohorts Only</title>
          <description>Participants with HIV-1 infection who 1) started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007, had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort, and 2) started raltegravir on or after 21 December 2007 and had at least 1 month prospective follow-up in the Raltegravir Cohort. These participants contributed data to the Concurrent Cohort and the Raltegravir Cohort.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="656"/>
            <count group_id="B2" value="296"/>
            <count group_id="B3" value="1681"/>
            <count group_id="B4" value="631"/>
            <count group_id="B5" value="3199"/>
            <count group_id="B6" value="154"/>
            <count group_id="B7" value="6617"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="44" upper_limit="55"/>
                    <measurement group_id="B2" value="49" lower_limit="44" upper_limit="55"/>
                    <measurement group_id="B3" value="44" lower_limit="39" upper_limit="50"/>
                    <measurement group_id="B4" value="47" lower_limit="41" upper_limit="53"/>
                    <measurement group_id="B5" value="42" lower_limit="34" upper_limit="50"/>
                    <measurement group_id="B6" value="50" lower_limit="45" upper_limit="57"/>
                    <measurement group_id="B7" value="44" lower_limit="37" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="422"/>
                    <measurement group_id="B4" value="174"/>
                    <measurement group_id="B5" value="873"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="1744"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="480"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="1259"/>
                    <measurement group_id="B4" value="457"/>
                    <measurement group_id="B5" value="2326"/>
                    <measurement group_id="B6" value="127"/>
                    <measurement group_id="B7" value="4873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Malignancy</title>
        <description>All-type malignancy, including both Acquired Immune Deficiency Syndrome (AIDS)-defining and non-AIDS-defining malignancy, was evaluated. Only the first occurrence of any malignancy type was counted for each participant.</description>
        <time_frame>Historical Cohort: up to 24 months (January 2006 to December 2007); Raltegravir and Concurrent Cohorts: up to 68 months (December 2007 to July 2013)</time_frame>
        <population>Intention-to-Treat analysis included follow-up until the end of the follow-up period for the cohort, regardless of whether or not raltegravir or other drugs were discontinued.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir Cohort</title>
            <description>Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.</description>
          </group>
          <group group_id="O2">
            <title>Historical Cohort</title>
            <description>Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.</description>
          </group>
          <group group_id="O3">
            <title>Concurrent Cohort</title>
            <description>Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Malignancy</title>
          <description>All-type malignancy, including both Acquired Immune Deficiency Syndrome (AIDS)-defining and non-AIDS-defining malignancy, was evaluated. Only the first occurrence of any malignancy type was counted for each participant.</description>
          <population>Intention-to-Treat analysis included follow-up until the end of the follow-up period for the cohort, regardless of whether or not raltegravir or other drugs were discontinued.</population>
          <units>Events per 100 person-years of follow-up</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Person years of follow-up</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1150"/>
                <count group_id="O2" value="2608"/>
                <count group_id="O3" value="3984"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Person years of follow-up</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2712"/>
                <count group_id="O2" value="2895"/>
                <count group_id="O3" value="10035"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" lower_limit="0.93" upper_limit="1.80"/>
                    <measurement group_id="O2" value="1.17" lower_limit="0.84" upper_limit="1.64"/>
                    <measurement group_id="O3" value="0.81" lower_limit="0.65" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Clinically Important Hepatic Events</title>
        <description>Clinically important hepatic events were defined as either 1) hepatic encephalopathy (stage III or IV), or 2) discontinuation of raltegravir use where liver toxicity was listed as the reason for discontinuation.</description>
        <time_frame>Historical Cohort: up to 24 months (January 2006 to December 2007); Raltegravir and Concurrent Cohorts: up to 68 months (December 2007 to July 2013)</time_frame>
        <population>Intention-to-Treat analysis included follow-up until the end of the follow-up period for the cohort, regardless of whether or not raltegravir or other drugs were discontinued.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir Cohort</title>
            <description>Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.</description>
          </group>
          <group group_id="O2">
            <title>Historical Cohort</title>
            <description>Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.</description>
          </group>
          <group group_id="O3">
            <title>Concurrent Cohort</title>
            <description>Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Clinically Important Hepatic Events</title>
          <description>Clinically important hepatic events were defined as either 1) hepatic encephalopathy (stage III or IV), or 2) discontinuation of raltegravir use where liver toxicity was listed as the reason for discontinuation.</description>
          <population>Intention-to-Treat analysis included follow-up until the end of the follow-up period for the cohort, regardless of whether or not raltegravir or other drugs were discontinued.</population>
          <units>Events per 100 person-years of follow-up</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Person years of follow-up</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1150"/>
                <count group_id="O2" value="2608"/>
                <count group_id="O3" value="3984"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Person years of follow-up</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2750"/>
                <count group_id="O2" value="2891"/>
                <count group_id="O3" value="10086"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.04" upper_limit="0.34"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.61" upper_limit="1.32"/>
                    <measurement group_id="O3" value="0.28" lower_limit="0.19" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Lipodystrophy</title>
        <description>Lipodystrophy events were defined as the first report for either 1) loss of fat from extremities, buttocks, or face, or 2) accumulation of fat in abdomen, neck, breasts, or other defined location.</description>
        <time_frame>Historical Cohort: up to 24 months (January 2006 to December 2007); Raltegravir and Concurrent Cohorts: up to 68 months (December 2007 to July 2013)</time_frame>
        <population>Intention-to-Treat analysis included follow-up until the end of the follow-up period for the cohort, regardless of whether or not raltegravir or other drugs were discontinued.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir Cohort</title>
            <description>Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.</description>
          </group>
          <group group_id="O2">
            <title>Historical Cohort</title>
            <description>Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.</description>
          </group>
          <group group_id="O3">
            <title>Concurrent Cohort</title>
            <description>Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Lipodystrophy</title>
          <description>Lipodystrophy events were defined as the first report for either 1) loss of fat from extremities, buttocks, or face, or 2) accumulation of fat in abdomen, neck, breasts, or other defined location.</description>
          <population>Intention-to-Treat analysis included follow-up until the end of the follow-up period for the cohort, regardless of whether or not raltegravir or other drugs were discontinued.</population>
          <units>Events per 100 person-years of follow-up</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Person years of follow-up</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1150"/>
                <count group_id="O2" value="2608"/>
                <count group_id="O3" value="3984"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Person years of follow-up</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2750"/>
                <count group_id="O2" value="2893"/>
                <count group_id="O3" value="10033"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.05" upper_limit="0.39"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.73" upper_limit="1.48"/>
                    <measurement group_id="O3" value="0.64" lower_limit="0.50" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of All-Cause Mortality</title>
        <description>All participant deaths were recorded</description>
        <time_frame>Historical Cohort: up to 24 months (January 2006 to December 2007); Raltegravir and Concurrent Cohorts: up to 68 months (December 2007 to July 2013)</time_frame>
        <population>Intention-to-Treat analysis included follow-up until the end of the follow-up period for the cohort, regardless of whether or not raltegravir or other drugs were discontinued.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir Cohort</title>
            <description>Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.</description>
          </group>
          <group group_id="O2">
            <title>Historical Cohort</title>
            <description>Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.</description>
          </group>
          <group group_id="O3">
            <title>Concurrent Cohort</title>
            <description>Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-Cause Mortality</title>
          <description>All participant deaths were recorded</description>
          <population>Intention-to-Treat analysis included follow-up until the end of the follow-up period for the cohort, regardless of whether or not raltegravir or other drugs were discontinued.</population>
          <units>Events per 100 person-years of follow-up</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Person years of follow-up</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1150"/>
                <count group_id="O2" value="2608"/>
                <count group_id="O3" value="3984"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Person years of follow-up</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2782"/>
                <count group_id="O2" value="2913"/>
                <count group_id="O3" value="10149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.58" upper_limit="1.29"/>
                    <measurement group_id="O2" value="1.27" lower_limit="0.92" upper_limit="1.75"/>
                    <measurement group_id="O3" value="0.68" lower_limit="0.54" upper_limit="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Per protocol, adverse events were not collected as part of the study database; therefore, none were collected and the number at risk is zero</desc>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir Cohort</title>
          <description>Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.</description>
        </group>
        <group group_id="E2">
          <title>Historical Cohort</title>
          <description>Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.</description>
        </group>
        <group group_id="E3">
          <title>Concurrent Cohort</title>
          <description>Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

